ISRCTN70977225已完成不适用
A randomised double-blind placebo-controlled pilot study of D-cycloserine-augmented exposure therapy in adolescents with obsessive-compulsive disorder
Institute of Psychiatry, Kings College London (UK)0 个研究点目标入组 24 人开始时间: 2009年2月5日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV) diagnosis of OCD
- •2. Aged 12 to 18 years
- •3. Either sex
- •4. Any ethnicity, religious background or sexual orientation
- •5. Referred to the National and Specialist OCD Clinic at Maudsley Hospital
- •6. If on medication, this should be stable for 12 weeks and not be changed during the course of the trial
- •7. Provision of written informed consent (patient and carer)
排除标准
- •1. Current diagnosis of psychosis, current alcohol or substance abuse/dependence
- •2. English too poor to engage in treatment
- •3. Severe disabling neurological disorder
- •4. Medical contraindication to cycloserine, including epilepsy and porphyria
- •5. A diagnosed global learning disability or pervasive developmental disorder
- •6. Characteristics interfering with completion of treatment, e.g. life threatening or unstable medical illness
- •7. Pregnancy
- •8. Not suitable for CBT (selective mutism, lack of insight or motivation for change)
研究者
相似试验
进行中（未招募）
1 期
A randomised double-blind placebo-controlled pilot study of D-cycloserine-augmented exposure therapy in adolescents with obsessive-compulsive disorderEUCTR2008-006947-38-GBKing's College London (Institute of Pyschiatry)24
进行中（未招募）
1 期
Trial of oxytocin for the treatment of emotional withdrawal symptoms and for relapse prevention in abstinent heroin dependent individualsOpioid dependence. The study will be investigating the efficacy of Syntocinon (oxytocin) on treating the withdrawal symptoms and cravings that opioid (e.g. almost always heroin) dependent individuals experience following detoxification.MedDRA version: 20.0 Level: LLT Classification code 10057379 Term: Addiction relapse System Organ Class: 100000004873MedDRA version: 20.0 Level: LLT Classification code 10001126 Term: Addiction any drug System Organ Class: 100000004873EUCTR2014-002708-26-GBniversity of Surrey3
招募中
不适用
Immunoglobulin therapy in Lung TransplantTransplantationRespiratory - Other respiratory disorders / diseasesACTRN12618001394235The Alfred Hospital40
已完成
不适用
A randomised, double-blinded clinical study of LC for systemic lupus erythematosus patientsSystemic lupus erythematosus (SLE)Musculoskeletal DiseasesISRCTN81818883Department of Health (Taiwan) - Executive Yuan90
尚未招募
3 期
The Myer Foundation Study into Multiple SclerosisRelapsing remitting multiple sclerosisNeurological - Multiple sclerosisACTRN12606000359538Melbourne Health20